Enasidenib Mesylate
Sponsors
M.D. Anderson Cancer Center, City of Hope Medical Center, Jonsson Comprehensive Cancer Center, Children's Oncology Group
Conditions
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaIDH2 Gene MutationMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Phase 1
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
WithdrawnNCT04655391
Start: 2022-06-25End: 2023-12-15Updated: 2022-06-09
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruitingNCT05441514
Start: 2022-11-03End: 2027-05-03Updated: 2025-09-16
Phase 2
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RecruitingNCT03683433
Start: 2018-09-18End: 2027-09-20Target: 50Updated: 2026-03-05
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
RecruitingNCT03728335
Start: 2019-07-11End: 2027-01-11Target: 35Updated: 2026-03-13
CPX-351 Plus Enasidenib for Relapsed AML
Active, not recruitingNCT03825796
Start: 2019-04-12End: 2024-09-01Updated: 2023-09-28
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Active, not recruitingNCT04203316
Start: 2023-08-14End: 2026-10-03Updated: 2026-01-09